Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie

Stock Track01-13

REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.

Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105958376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105958376","market":"sg","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie","media":"Stock Track","content":"<p>REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.</p><p>Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-13 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.</p><p>Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1105958376","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105958376","pubTimestamp":1768267855,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|与艾伯维达成独家授权协议REMEGEN盘前大涨8.84%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105958376","isCrawlerRequest":true}